Is Novo Nordisk Stock a Buy?
It hasn't been a great period for investors in Novo Nordisk (NVO -5.27%) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs. Its shares are down by more than 20% in the last 12 months, and, given a few new competitive developments, the next 12 months might not see much in the way of relief for shareholders unless there's an upset of some kind.
Explainer: What Wegovy's inclusion in Medicare price negotiation means for patients, company
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's what Wall Street analysts say about the inclusion:
Novo Nordisk shares fall after Ozempic, Wegovy selected for Medicare price negotiations
Novo Nordisk (NYSE:NVO) shares plummeted after the US Medicare program announced it plans to include the firm's weight loss medications in its second round of price negotiations. Shares of the Danish drugmaker fell 4.4% to about $79 on Friday morning, bringing the stock's losses to 25.5% in the last 12 months.
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Analysts at Argus Research say the stock is now trading at 22 times its estimated 2025 earnings.
US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.
Novo Nordisk says high-dose semaglutide trial shows 20.7% weight loss
Novo Nordisk said on Friday that a late-stage trial with 7.2 milligram (mg) of semaglutide, a high-dose version of the active ingredient used in its blockbuster obesity drug Wegovy, helped overweight patients cut their weight by 20.7%.
Finally An Attractive Entry Point Into Novo Nordisk
Finally An Attractive Entry Point Into Novo Nordisk
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.
Novo Nordisk: Excellent Opportunity To Buy The Dip
Novo Nordisk presents a compelling 'Strong Buy' opportunity with a 51% upside potential. NVO's financial strength is evident through its 74% historical average ROIC, 85% gross margin, and substantial R&D investments, ensuring future growth. The company's valuation is attractive with a forward P/E ratio of 27 for FY2024 and 17 for FY2027, indicating significant undervaluation.
Novo-Nordisk Stock (NVO) Could Be Longer-Term Turnaround Play
Obesity is rising and in the last 35 years, has more than doubled. The world population in 1999 to today is 42% or 22 million adults with a body mass index of 40 or higher.
Novo Nordisk excitement starts to build ahead of February results
Novo Nordisk (NYSE:NVO) fourth-quarter results on February 5, 2025, will be a big announcement for Europe's largest company given the febrile excitement surrounding its blockbuster appetite-reducing / weight-loss treatments Wegovy and Ozempic. City big hitters are already getting their ducks in a row ahead of the numbers and US bank JP Morgan sees sales in the fourth quarter at DKr82.6bn (£9 billion), or 2% ahead of consensus due to its higher forecasts for Wegovy sales.
Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
In the most recent trading session, Novo Nordisk (NVO) closed at $84.62, indicating a -1.9% shift from the previous trading day.
